EP Patent

EP1608641A1 — A process for the synthesis of losartan potassium

Assigned to Ipca Laboratories Ltd · Expires 2005-12-28 · 20y expired

What this patent protects

A process for the synthesis of Losartan Postassium by reacting Trityl Losartan in a primary alcohol with potassium tertiary alkoxide.

USPTO Abstract

A process for the synthesis of Losartan Postassium by reacting Trityl Losartan in a primary alcohol with potassium tertiary alkoxide.

Drugs covered by this patent

Patent Metadata

Patent number: EP1608641A1
Jurisdiction: EP
Classification: —
Expires: 2005-12-28
Drug substance claim: No
Drug product claim: No
Assignee: Ipca Laboratories Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.